Dyadic International (DYAI) Stock Price, Quote & News

Company Profile

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products f...

Industry: Biotechnology

Sector: Healthcare

Phone: 561 743 8333

Fax: 561 743 8343

Website: www.dyadic.com

Address:

1044 North U.S. Highway One, Suite 201, Jupiter, United States

Jirish72 Oct. 24 at 12:10 PM

$DYAI this is going to fly soon

1 · Reply

Glopolon Oct. 23 at 2:27 PM

$DYAI https://www.gurufocus.com/news/3156614/dyadic-international-dyai-receives-a-buy-rating-from-hc-wainwright-dyai-stock-news

0 · Reply

JarvisFlow Oct. 23 at 10:41 AM

HC Wainwright & Co. updates rating for Dyadic International ( $DYAI ) to Buy, target set at 3.

0 · Reply

MartyCortez Oct. 22 at 3:20 PM

$BYND low float $DYAI next.

0 · Reply

ed29 Oct. 19 at 1:36 PM

$DYAI @PLX_BULLS check this out.

2 · Reply

Glopolon Oct. 16 at 2:38 AM

$DYAI Here is a reminder about it https://www.bioprocessintl.com/deal-making/cepi-s-100-days-mission-gets-a-fungal-boost-dyadic-fbs-lead-the-way

1 · Reply

Glopolon Oct. 16 at 2:37 AM

$DYAI This is Rino Rappuoli, the Fondazione Biotecnopolo di Siena guy heading the $170M euro foundation study. https://royalsociety.org/people/rino-rappuoli-12894/

0 · Reply

Glopolon Oct. 16 at 12:42 AM

$DYAI Nirsevimab is $520 per dose. Background on RSV and Nirsevimab https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers

0 · Reply

Glopolon Oct. 16 at 12:40 AM

$DYAI https://d2ghdaxqb194v2.cloudfront.net/2606/198451.pdf 5-fold stronger RSV neutralization over Nirsevimab, 17-fold stronger than Clesrovimab.

0 · Reply

Glopolon Oct. 16 at 12:38 AM

$DYAI Dyadic posted new data in most recent pdf, from OCMS re: the RSV mAb that is being funded by Gates Foundation grant. https://www.linkedin.com/posts/ocms-bio_data-summary-activity-7376269126736019456-_kpO

0 · Reply

Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments

Sep 4, 2025, 9:00 AM EDT - 7 weeks ago

Dyadic to Present at Investor Conferences and BPI East

Aug 13, 2025, 7:51 PM EDT - 2 months ago

Dyadic International, Inc. (DYAI) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:01 PM EDT - 2 months ago

Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Aug 5, 2025, 4:11 PM EDT - 2 months ago

Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jul 31, 2025, 8:47 AM EDT - 3 months ago

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Jul 30, 2025, 4:02 PM EDT - 3 months ago

Dyadic International, Inc. Announces Proposed Public Offering of Common Stock

Jul 2, 2025, 4:00 PM EDT - 4 months ago

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

Jun 2, 2025, 8:35 AM EDT - 5 months ago

Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

May 14, 2025, 11:31 PM EDT - 5 months ago

Dyadic International, Inc. (DYAI) Q1 2025 Earnings Call Transcript

May 1, 2025, 3:00 PM EDT - 6 months ago

Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Apr 16, 2025, 2:00 PM EDT - 6 months ago

Dyadic to Present at World Vaccine Congress | Washington

Mar 26, 2025, 10:58 PM EDT - 7 months ago

Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:05 PM EDT - 7 months ago

Dyadic Reports 2024 Year-End Financial Results and Business Updates

Mar 12, 2025, 4:00 PM EDT - 8 months ago

Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025

Mar 6, 2025, 8:30 AM EST - 8 months ago

Dyadic to Attend Multiple Industry Events in March

Jan 6, 2025, 8:30 AM EST - 10 months ago

Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference

Nov 21, 2024, 8:30 AM EST - 1 year ago

Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology

Nov 16, 2024, 8:16 PM EST - 1 year ago

Dyadic International, Inc. (DYAI) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:30 PM EST - 1 year ago

Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Dyadic Expands Global Presence with Participation in Key Industry Events

Sep 23, 2024, 9:50 AM EDT - 1 year ago

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

Aug 13, 2024, 11:05 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 4:00 PM EDT - 1 year ago

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

May 30, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Attend Industry Events in June

May 17, 2024, 10:15 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:00 PM EDT - 1 year ago

Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry and Investor Events in May

Apr 30, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Mar 28, 2024, 10:22 PM EDT - 1 year ago

Dyadic International, Inc. (DYAI) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 4:00 PM EDT - 1 year ago

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Mar 28, 2024, 8:30 AM EDT - 1 year ago

Dyadic Announces Change in Board and Management Leadership Roles

Mar 27, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Industry Events in April

Mar 26, 2024, 8:30 AM EDT - 1 year ago

Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications

Mar 21, 2024, 8:30 AM EDT - 1 year ago

Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California

Mar 14, 2024, 4:30 PM EDT - 1 year ago

Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024

Mar 11, 2024, 9:57 AM EDT - 1 year ago

CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 11, 2024, 8:30 AM EDT - 1 year ago

Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

Mar 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend Industry Events in March

Feb 28, 2024, 8:30 AM EST - 1 year ago

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

Feb 23, 2024, 2:00 AM EST - 1 year ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 21, 2024, 8:30 AM EST - 1 year ago

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

Feb 13, 2024, 8:30 AM EST - 1 year ago

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Feb 6, 2024, 8:30 AM EST - 1 year ago

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

Feb 1, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

Jan 22, 2024, 8:00 AM EST - 1 year ago

Dyadic International, Inc Invites You to Join Us at The Microcap Conference

Jan 2, 2024, 8:30 AM EST - 1 year ago

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

Nov 30, 2023, 8:30 AM EST - 2 years ago

Dyadic Attends Investor Events in December

Jirish72 Oct. 24 at 12:10 PM

$DYAI this is going to fly soon

1 · Reply

Glopolon Oct. 23 at 2:27 PM

$DYAI https://www.gurufocus.com/news/3156614/dyadic-international-dyai-receives-a-buy-rating-from-hc-wainwright-dyai-stock-news

0 · Reply

JarvisFlow Oct. 23 at 10:41 AM

HC Wainwright & Co. updates rating for Dyadic International ( $DYAI ) to Buy, target set at 3.

0 · Reply

MartyCortez Oct. 22 at 3:20 PM

$BYND low float $DYAI next.

0 · Reply

ed29 Oct. 19 at 1:36 PM

$DYAI @PLX_BULLS check this out.

2 · Reply

Glopolon Oct. 16 at 2:38 AM

$DYAI Here is a reminder about it https://www.bioprocessintl.com/deal-making/cepi-s-100-days-mission-gets-a-fungal-boost-dyadic-fbs-lead-the-way

1 · Reply

Glopolon Oct. 16 at 2:37 AM

$DYAI This is Rino Rappuoli, the Fondazione Biotecnopolo di Siena guy heading the $170M euro foundation study. https://royalsociety.org/people/rino-rappuoli-12894/

0 · Reply

Glopolon Oct. 16 at 12:42 AM

$DYAI Nirsevimab is $520 per dose. Background on RSV and Nirsevimab https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers

0 · Reply

Glopolon Oct. 16 at 12:40 AM

$DYAI https://d2ghdaxqb194v2.cloudfront.net/2606/198451.pdf 5-fold stronger RSV neutralization over Nirsevimab, 17-fold stronger than Clesrovimab.

0 · Reply

Glopolon Oct. 16 at 12:38 AM

0 · Reply

Tarrytabby Oct. 14 at 1:45 PM

$DYAI Presentation World Vaccine Congress/ Amsterdam October 13-16, 2025 https://d2ghdaxqb194v2.cloudfront.net/2606/198451.pdf

0 · Reply

Tarrytabby Oct. 14 at 1:42 PM

$DYAI Dyadic presents at the Sidoti Small Cap Conference https://www.youtube.com/watch?v=L-x-DCX6Adw

0 · Reply

Tarrytabby Oct. 6 at 3:31 PM

$DYAI here are the news: $750,000 milestone payments - keep it up

0 · Reply

Tarrytabby Oct. 1 at 6:07 PM

$DYAI I could imagine that speculative funds/investors are stocking up here at the beginning of the quarter or there will be news.

0 · Reply

Jbaffs Oct. 1 at 3:36 PM

$DYAI After tomorrows close they will have been above $1 for ten days in a row which removes the delisting risk.

2 · Reply

Jbaffs Sep. 29 at 3:12 PM

$DYAI the worst stock board ever

1 · Reply

Glopolon Sep. 23 at 3:11 PM

$DYAI $5 target from Hallum https://m.uk.investing.com/news/analyst-ratings/craighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630?ampMode=1#origin=https%3A%2F%2Fwww.google.com%2F&cap=swipe,education&webview=1&dialog=1&viewport=natural&visibilityState=prerender&prerenderSize=1&viewerUrl=https%3A%2F%2Fwww.google.com%2Famp%2Fs%2Fm-uk-investing-com.cdn.ampproject.org%2Fc%2Fs%2Fm.uk.investing.com%2Fnews%2Fanalyst-ratings%2Fcraighallum-initiates-dyadic-international-stock-with-buy-rating-93CH-4254630%3FampMode=1&usqp=mq331AQIUAKwASCAAgM%25253D&amp_kit=1

0 · Reply

Glopolon Sep. 22 at 10:19 PM

$DYAI From Aug 1, 2005, re: Fermbox Bio https://www.cbs42.com/business/press-releases/ein-presswire/836232491/biotech-in-focus-indias-biomanufacturing-momentum-and-fermbox-bios-role-in-precision-fermentation/

0 · Reply

Glopolon Sep. 21 at 11:41 PM

$DYAI The ability of a protein production platform to make human like glycans opens the door to monoclonal antibody production.

0 · Reply

Glopolon Sep. 21 at 11:39 PM

$DYAI One of the more important advances to the C1 platform since the Dupont deal was the creation of a line that can produce human-like glycan structures. https://dyadic.com/dyadic-announces-achieving-human-like-glycan-structures-from-its-engineered-c1-cell-line/

0 · Reply

Glopolon Sep. 21 at 8:08 PM

$DYAI The industrial production rights have since ended, as well.. So that is opening up that arena again.

0 · Reply

Glopolon Sep. 21 at 8:07 PM

$DYAI It is not accurate to say they are pre-revenue. They sold their industrial production rights to Dupont for $70M in 2015, and prior to that, they were getting revenue from their protein production platform. They have refined the C1 platform since then, and they do not have a lot of R&D spend.

0 · Reply

Market Cap	41.25M
Revenue (ttm)	3.50M
Net Income (ttm)	-5.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-166.00%
Debt to Equity Ratio	0.00

Volume	101,300
Avg Vol	122,966
Day's Range	N/A - N/A
Shares Out	36.19M
Stochastic %K	66%
Beta	1.00
Analysts	Strong Sell
Price Target	$5.67